mercredi 1 avril 2020

Onco Actu du 1er avril 2020


4.12 BIOPSIES LIQUIDES



Grail Multi-Cancer Test Meets Validation Goals; Patients to Receive Results Under New Pilot [Genome Web]











New blood test study uses artificial intelligence to identify cancer. But it’s not ready for patients yet. [Cancer Research UK]










5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



Drug Combination Could Boost the Effectiveness of Immunotherapy against Pancreatic Cancer [Memorial Sloan-Kettering Cancer Center]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



With latest FDA submission, Bristol Myers keeps pace with Celgene milestones [Biopharma Dive]











Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA [bluebird bio]











Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T [EndPoints]











Could CAR-T Version 2.0 Be on the Horizon? [Children's Hospital Los Angeles]











5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



Motion denied: Gilead still on the hook for $1.5B in damages over CAR-T patent dispute with Bristol Myers Squibb [EndPoints]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



EMA Recommends Granting a Marketing Authorisation for Isatuximab [ESMO]











6.15 LUTTE CONTRE LES CANCERS - COVID-19



MD Anderson implements proactive measures due to 2019 novel coronavirus disease (COVID-19) [MD Anderson Cancer Center]











NICE publishes second set of rapid COVID-19 guidelines [NICE]










COVID-19 Infection and Related Challenges in Aviano Cancer Centre in Italy [ESMO]